WARSAW, Ind., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2024.
Third Quarter 2024 and Recent Business Highlights
David Bailey, President & CEO of OrthoPediatrics, commented, “The third quarter results represent yet another strong performance for OrthoPediatrics in which we continued our positive momentum and executed our strategic initiatives. With multiple levers driving our growth, we saw strength across all business segments as Trauma and Deformity, Scoliosis, and OPSB all contributed to further establishing our dominant market share position within pediatric orthopedics. As we look ahead, we are confident in the remainder of 2024 and ending the year in a position of strength. Even more, we are excited about our long-term outlook as we expect to continue extending our growth while we maintain healthy gross margins and generate substantial EBITDA, all while we surround the children's hospital with everything needed to optimize pediatric care."
Third Quarter 2024 Financial Results
Total revenue for the third quarter of 2024 was $54.6 million, a 37% increase compared to $40.0 million for the same period last year. U.S. revenue for the third quarter of 2024 was $42.7 million, a 45% increase compared to $29.4 million for the same period last year, representing 78% of total revenue. The increase in domestic revenue in the third quarter of 2024 was driven by additional market share gains across Trauma and Deformity, Scoliosis, and OPSB. International revenue for the third quarter of 2024 was $11.9 million, a 12% increase compared to $10.6 million for the same period last year, representing 22% of total revenue. Growth in the quarter was primarily led by Scoliosis revenue.
Trauma and Deformity revenue for the third quarter of 2024 was $37.6 million, a 31% increase compared to $28.8 million for the same period last year. This growth was driven primarily by strong growth across numerous product lines, as well as the addition of Boston O&P. Scoliosis revenue was $15.6 million, a 52% increase compared to $10.3 million for the third quarter of 2023. The growth was driven primarily by increased international scoliosis revenue, new users of spine systems, RESPONSE 5.5/6.0, as well as 7D. Sports Medicine/Other revenue for the third quarter of 2024 was $1.3 million, a 50% increase compared to $0.9 million for the same period last year.
Gross profit for the third quarter of 2024 was $40.1 million, a 29% increase compared to $31.0 million for the same period last year. Gross profit margin for the third quarter of 2024 was 73%, compared to 77% for the same period last year. The change in gross margin was primarily driven by changes in product mix due to increased 7D unit sales at lower margin, set sales internationally, as well as less favorable purchase price variance compared to the third quarter of 2023.
Total operating expenses for the third quarter of 2024 were $45.6 million, a 29% increase compared to $35.5 million for the same period last year. The increase was mainly driven by the addition of Boston O&P, as well as increased commission expense and incremental personnel required to support the ongoing growth of the Company.
Sales and marketing expenses increased $2.8 million, or 20%, to $16.8 million in the third quarter of 2024. The increase was driven primarily by increased sales commission expenses coupled with additional employees to support the OPSB.
Research and development expenses increased negligibly to $2.6 million in the third quarter of 2024. The slight increase was driven by timing of external development expenses.
General and administrative expenses increased $8.3 million, or 46%, to $26.3 million in the third quarter of 2024. The increase was driven primarily by the addition of Boston O&P, increased depreciation and amortization as well as personnel and resources to support the continued expansion of the business.
Total other expense was $3.6 million for the third quarter of 2024, compared to $0.8 million of other income for the same period last year. The increase was driven by a one-time refinancing expense of $3.2 million.
Net loss for the third quarter of 2024 was $7.9 million, compared to $4.6 million for the same period last year. Net loss per share for the period was $0.34 per basic and diluted share, compared to $0.20 per basic and diluted share for the same period last year.
Adjusted EBITDA for the third quarter of 2024 was $4.0 million as compared to $3.6 million for the third quarter of 2023.
Weighted average basic and diluted shares outstanding for the three months ended September 30, 2024, was 23,171,249 shares.
As of September 30, 2024, cash, cash equivalents, short-term investments and restricted cash were $78.1 million compared to $82.3 million as of December 31, 2023.
Full Year 2024 Financial Guidance
For the full year of 2024, the Company increased its revenue guidance from $200 million to $203 million to $202 million to $204 million , representing growth of 36% to 37% over 2023 revenue. The Company reiterated annual set deployment to be less than $20 million and reiterated $8 million to $9 million of Adjusted EBITDA for the full year of 2024.
Conference Call
OrthoPediatrics will host a conference call on Thursday, November 7, 2024, at 8:00 a.m. ET to discuss the results. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.orthopediatrics.com, on the Investors page in the Events & Presentations section. The webcast will be available for replay for at least 90 days after the event.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of U.S. federal securities laws. You can identify forward-looking statements by the use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "believe," "estimate," "project," "target," "predict," "intend," "future," "goals," "potential,” "objective," "would" and other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, and the other risks, uncertainties and factors set forth under "Risk Factors" in OrthoPediatrics’ Annual Report on Form 10-K filed with the SEC on March 8, 2024, as updated and supplemented by our other SEC reports filed from time to time, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements;. Forward-looking statements speak only as of the date they are made. OrthoPediatrics assumes no obligation to update forward-looking statements to reflect actual results, subsequent events, or circumstances or other changes affecting such statements except to the extent required by applicable securities laws.
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures such as organic revenue, adjusted loss per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). Sales on an organic basis excludes from our reported net revenue growth the impacts of revenue from any acquired business that have been owned for less than one year. We believe that providing the non-GAAP organic revenue is useful as a way to measure and evaluate our underlying performance consistently across the periods presented. Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, plus the accreted interest attributable to acquisition installment payables, the fair value adjustment of contingent consideration, acquisition related costs, loss on early extinguishment of debt, nonrecurring Pega conversion fees, and minimum purchase commitment costs. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other expense, provision for income taxes (benefit), depreciation and amortization, tradename impairment, stock-based compensation expense, fair value adjustment of contingent consideration, acquisition related costs, nonrecurring PEGA conversion fees, Midcap financing termination loss, and the cost of minimum purchase commitments. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company’s operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using these adjusted measures on a supplemental basis. The Company’s definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of reported GAAP net revenue to non-GAAP organic revenue, GAAP diluted loss per share to non-GAAP diluted loss and net loss to non-GAAP Adjusted EBITDA.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 70 systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
| ORTHOPEDIATRICS CORP. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In Thousands, Except Share Data) | |||||||
| September 30, 2024 | December 31, 2023 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 51,047 | $ | 31,055 | |||
| Restricted cash | 1,998 | 1,972 | |||||
| Short-term investments | 25,017 | 49,251 | |||||
| Accounts receivable - trade, net of allowances of $1,025 and $1,373, respectively | 42,827 | 34,617 | |||||
| Inventories, net | 120,934 | 105,851 | |||||
| Prepaid expenses and other current assets | 6,489 | 3,750 | |||||
| Total current assets | 248,312 | 226,496 | |||||
| Property and equipment, net | 54,765 | 41,048 | |||||
| Other assets: | |||||||
| Amortizable intangible assets, net | 65,955 | 69,275 | |||||
| Goodwill | 91,262 | 83,699 | |||||
| Other intangible assets | 18,744 | 15,287 | |||||
| Other non-current assets | 10,256 | 2,940 | |||||
| Total other assets | 186,217 | 171,201 | |||||
| Total assets | $ | 489,294 | $ | 438,745 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable - trade | $ | 11,647 | $ | 12,649 | |||
| Accrued compensation and benefits | 13,221 | 11,325 | |||||
| Current portion of long-term debt with affiliate | 158 | 152 | |||||
| Current portion of acquisition installment payable | 1,325 | 10,149 | |||||
| Other current liabilities | 8,274 | 7,391 | |||||
| Total current liabilities | 34,625 | 41,666 | |||||
| Long-term liabilities: | |||||||
| Long-term loan | 23,948 | 9,297 | |||||
| Long-term convertible loan | 47,831 | — | |||||
| Long-term debt with affiliate, net of current portion | 491 | 611 | |||||
| Other long-term debt, net of current portion | 244 | — | |||||
| Acquisition installment payable, net of current portion | 2,412 | 3,551 | |||||
| Deferred income taxes | 4,025 | 5,483 | |||||
| Other long-term liabilities | 4,799 | 1,112 | |||||
| Total long-term liabilities | 83,750 | 20,054 | |||||
| Total liabilities | 118,375 | 61,720 | |||||
| Stockholders' equity: | |||||||
| Common stock, $0.00025 par value; 50,000,000 shares authorized; 24,214,046 shares and 23,378,408 shares issued as of September 30, 2024 and December 31, 2023, respectively | 6 | 6 | |||||
| Additional paid-in capital | 597,009 | 580,287 | |||||
| Accumulated deficit | (219,495 | ) | (197,742 | ) | |||
| Accumulated other comprehensive loss | (6,601 | ) | (5,526 | ) | |||
| Total stockholders' equity | 370,919 | 377,025 | |||||
| Total liabilities and stockholders' equity | $ | 489,294 | $ | 438,745 | |||
| ORTHOPEDIATRICS CORP. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (In Thousands, Except Share and Per Share Data) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net revenue | $ | 54,573 | $ | 39,972 | $ | 152,060 | $ | 111,119 | |||||||
| Cost of revenue | 14,513 | 9,019 | 39,027 | 26,580 | |||||||||||
| Gross profit | 40,060 | 30,953 | 113,033 | 84,539 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 16,750 | 13,942 | 47,512 | 40,024 | |||||||||||
| General and administrative | 26,299 | 17,973 | 78,358 | 54,242 | |||||||||||
| Tradename impairment | — | 985 | — | 985 | |||||||||||
| Research and development | 2,577 | 2,561 | 8,118 | 7,973 | |||||||||||
| Total operating expenses | 45,626 | 35,461 | 133,988 | 103,224 | |||||||||||
| Operating loss | (5,566 | ) | (4,508 | ) | (20,955 | ) | (18,685 | ) | |||||||
| Other expense (income): | |||||||||||||||
| Interest expense, net | 404 | 21 | 1,302 | 105 | |||||||||||
| Loss on early extinguishment of debt | 3,230 | — | 3,230 | — | |||||||||||
| Fair value adjustment of contingent consideration | — | — | — | (2,974 | ) | ||||||||||
| Other income (expense), net | (63 | ) | (787 | ) | 33 | (1,407 | ) | ||||||||
| Total other expense (income), net | 3,571 | (766 | ) | 4,565 | (4,276 | ) | |||||||||
| Loss before income taxes | $ | (9,137 | ) | $ | (3,742 | ) | $ | (25,520 | ) | $ | (14,409 | ) | |||
| Provision for income taxes (benefit) | (1,218 | ) | 849 | (3,767 | ) | (126 | ) | ||||||||
| Net loss | $ | (7,919 | ) | $ | (4,591 | ) | $ | (21,753 | ) | $ | (14,283 | ) | |||
| Weighted average common stock - basic and diluted | 23,171,249 | 22,762,823 | 23,046,155 | 22,646,087 | |||||||||||
| Net loss per share – basic and diluted | $ | (0.34 | ) | $ | (0.20 | ) | $ | (0.94 | ) | $ | (0.63 | ) | |||
| ORTHOPEDIATRICS CORP. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)(In Thousands) | |||||||
| Nine Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| OPERATING ACTIVITIES | |||||||
| Net loss | $ | (21,753 | ) | $ | (14,283 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Tradename Impairment | — | 985 | |||||
| Depreciation and amortization | 15,087 | 12,198 | |||||
| Stock-based compensation | 9,660 | 7,779 | |||||
| Loss on early extinguishment of debt | 3,230 | — | |||||
| Fair value adjustment of contingent consideration | — | (2,974 | ) | ||||
| Fair value adjustment of acquisition installment payable | 599 | 1,092 | |||||
| Deferred income taxes | (3,907 | ) | (899 | ) | |||
| Changes in certain current assets and liabilities: | |||||||
| Accounts receivable - trade | (5,178 | ) | (12,878 | ) | |||
| Inventories, net | (14,154 | ) | (22,198 | ) | |||
| Prepaid expenses and other current assets | (2,134 | ) | (196 | ) | |||
| Accounts payable - trade | (1,768 | ) | 11,492 | ||||
| Accrued expenses and other liabilities | 308 | 3,288 | |||||
| Other | (3,051 | ) | (2,909 | ) | |||
| Net cash used in operating activities | (23,061 | ) | (19,503 | ) | |||
| INVESTING ACTIVITIES | |||||||
| Acquisition of Boston O&P, net of cash acquired | (20,225 | ) | — | ||||
| Clinic acquisition, net of cash acquired | (475 | ) | — | ||||
| Acquisition of MedTech, net of cash acquired | — | (3,097 | ) | ||||
| Acquisition of Rhino assets | — | (546 | ) | ||||
| Investment in private companies | (380 | ) | — | ||||
| Sale of short-term marketable securities | 49,855 | 89,040 | |||||
| Purchase of short-term marketable securities | (25,000 | ) | (48,600 | ) | |||
| Purchases of property and equipment | (14,525 | ) | (13,042 | ) | |||
| Net cash (used in) provided by investing activities | (10,750 | ) | 23,755 | ||||
| FINANCING ACTIVITIES | |||||||
| Installment payment for ApiFix | (2,250 | ) | (2,000 | ) | |||
| Installment payment for MedTech | (1,250 | ) | — | ||||
| Proceeds from issuance of debt | 73,533 | — | |||||
| Payment on debt | (12,231 | ) | — | ||||
| Payment of debt issuance costs | (3,085 | ) | — | ||||
| Proceeds from exercise of stock options | — | 21 | |||||
| Payments on acquisition note | (928 | ) | — | ||||
| Payments on mortgage notes | (113 | ) | (107 | ) | |||
| Net cash provided by (used in) financing activities | 53,676 | (2,086 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 153 | (396 | ) | ||||
| NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 20,018 | 1,770 | |||||
| Cash, cash equivalents and restricted cash, beginning of period | $ | 33,027 | $ | 10,462 | |||
| Cash, cash equivalents and restricted cash, end of period | $ | 53,045 | $ | 12,232 | |||
| SUPPLEMENTAL DISCLOSURES | |||||||
| Cash paid for interest | $ | 1,381 | $ | 32 | |||
| Issuance of common shares to acquire Rhino | $ | — | $ | 478 | |||
| Transfer of instruments between property and equipment and inventory | $ | 966 | $ | 431 | |||
| Issuance of common shares for ApiFix installment | $ | 6,929 | $ | 6,178 | |||
| Issuance of common shares for MedTech installment | $ | 133 | $ | 2,274 | |||
| Right-of-use assets obtained in exchange for lease liabilities | $ | 3,220 | $ | 367 | |||
| Debt issuance costs not yet paid | $ | 260 | $ | — | |||
| ORTHOPEDIATRICS CORP. NET REVENUE BY GEOGRAPHY AND PRODUCT CATEGORY (Unaudited) (In Thousands) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| Product sales by geographic location: | 2024 | 2023 | 2024 | 2023 | |||||||||||
| U.S. | $ | 42,714 | $ | 29,360 | $ | 118,269 | $ | 82,748 | |||||||
| International | 11,859 | 10,612 | 33,791 | 28,371 | |||||||||||
| Total | $ | 54,573 | $ | 39,972 | $ | 152,060 | $ | 111,119 | |||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| Product sales by category: | 2024 | 2023 | 2024 | 2023 | |||||||||||
| Trauma and deformity | $ | 37,642 | $ | 28,806 | $ | 108,715 | $ | 79,715 | |||||||
| Scoliosis | 15,635 | 10,304 | 39,521 | 28,270 | |||||||||||
| Sports medicine/other | 1,296 | 862 | 3,824 | 3,134 | |||||||||||
| Total | $ | 54,573 | $ | 39,972 | $ | 152,060 | $ | 111,119 | |||||||
| ORTHOPEDIATRICS CORP. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited) (In Thousands) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net loss | $ | (7,919 | ) | $ | (4,591 | ) | $ | (21,753 | ) | $ | (14,283 | ) | |||
| Interest expense, net | 404 | 21 | 1,302 | 105 | |||||||||||
| Other (income) expense | (63 | ) | (787 | ) | 33 | (1,407 | ) | ||||||||
| Provision for income taxes (benefit) | (1,218 | ) | 849 | (3,767 | ) | (126 | ) | ||||||||
| Depreciation and amortization | 5,280 | 4,270 | 15,087 | 12,198 | |||||||||||
| Stock-based compensation | 3,922 | 2,364 | 9,660 | 7,779 | |||||||||||
| Tradename impairment loss | — | 985 | — | 985 | |||||||||||
| Fair value adjustment of contingent consideration | — | — | — | (2,974 | ) | ||||||||||
| Acquisition related costs | 117 | 10 | 504 | 209 | |||||||||||
| Nonrecurring Pega conversion fees | — | — | — | 277 | |||||||||||
| Loss on early extinguishment of debt | 3,230 | — | 3,230 | — | |||||||||||
| Minimum purchase commitment cost | 224 | 477 | 1,200 | 1,053 | |||||||||||
| Adjusted EBITDA | $ | 3,977 | $ | 3,598 | $ | 5,496 | $ | 3,816 | |||||||
| ORTHOPEDIATRICS CORP. RECONCILIATION OF DILUTED LOSS PER SHARE TO NON-GAAP ADJUSTED DILUTED LOSS PER SHARE (Unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Loss per share, diluted (GAAP) | $ | (0.34 | ) | $ | (0.20 | ) | $ | (0.94 | ) | $ | (0.63 | ) | |||
| Tradename impairment loss | — | 0.04 | — | 0.04 | |||||||||||
| Accretion of interest attributable to acquisition installment payable | — | 0.01 | — | 0.05 | |||||||||||
| Fair value adjustment of contingent consideration | — | — | — | (0.13 | ) | ||||||||||
| Acquisition related costs | 0.01 | — | 0.02 | 0.01 | |||||||||||
| Nonrecurring Pega conversion fees | — | — | — | 0.01 | |||||||||||
| Loss on early extinguishment of debt | 0.14 | — | 0.14 | — | |||||||||||
| Minimum purchase commitment cost | 0.01 | 0.02 | 0.05 | 0.05 | |||||||||||
| Loss per share, diluted (non-GAAP) | $ | (0.18 | ) | $ | (0.13 | ) | $ | (0.73 | ) | $ | (0.60 | ) | |||
| Last Trade: | US$22.33 |
| Daily Change: | -0.13 -0.58 |
| Daily Volume: | 256,348 |
| Market Cap: | US$540.830M |
November 26, 2024 August 05, 2024 August 05, 2024 May 06, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
